Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessWhat to Expect From UiPath’s Upcoming Q1 Earnings?

What to Expect From UiPath’s Upcoming Q1 Earnings?

Add to Favorite
Added to Favorite


RBC Capital analysts provided their outlook on UiPath Inc. (NYSE:PATH) ahead of the upcoming Q1/24 earnings, expected to be reported on Wednesday.
The analysts expect a slight upside to Q1 results vs. consensus ARR/revenue of $1.247 billion/$271 million or 28%/11% growth which is in line with guidance.
As for guidance, the fiscal 2024 ARR midpoint is $1.427.5 billion or 18.6% growth, which points to a net new ARR of $224 million or down 20% year-over-year. Additionally, 2024 midpoint revenue was guided to $1.255.5 billion, or up 18.6%, similar to 2023 revenue growth.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Sangamo Shares Plummet 56 percent as Pfizer Ends Hemophilia A Gene Therapy Partnership

Sangamo Therapeutics (NASDAQ:SGMO) faced a significant setback as Pfizer...

Astera Labs Downgraded to Market Perform Amid Valuation Concerns

Northland analysts downgraded Astera Labs (NASDAQ:ALAB) from Outperform to...